LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Historical Holders from Q2 2015 to Q4 2025

Type / Class: Equity / COMMON STOCK
Symbol: LXRX on Nasdaq
Shares outstanding: 363,214,619
Price per share: $1.15
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 255,139,258
Total reported value: $344,428,817
% of total 13F portfolios: 0%
Share change: -1,196,786
Value change: -$1,111,877
Avg buy value change: +0%
Avg sell value change: -0%
Number of holders: 121

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	10%	+9%	$24,026,647	+$2,264,433	38,137,535	+10%	FMR LLC	30 Jun 2025

As of 30 Sep 2025, LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) has 121 institutional shareholders filing 13F forms. They hold 255,139,258 shares. of 363,214,619 outstanding shares (70%) .

Top 25 institutional shareholders own 69% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
Artal Group S.A.	37%	136,180,481	0%	24%	$183,843,649
Siren, L.L.C.	11%	38,918,903	0%	2.1%	$52,540,519
FMR LLC	11%	38,679,748	+1.4%	0%	$52,217,659
VANGUARD GROUP INC	2.6%	9,521,874	+7.6%	0%	$12,854,530
MILLENNIUM MANAGEMENT LLC	1.1%	3,830,660	+133%	0%	$5,171,391
BlackRock, Inc.	0.93%	3,394,972	+1.2%	0%	$4,583,212
Sessa Capital IM, L.P.	0.83%	3,000,000	0%	0.1%	$4,050,000
CITADEL ADVISORS LLC	0.73%	2,634,027		0%	$3,555,936
CIBC Private Wealth Group LLC	0.66%	2,400,257	-2%	0.01%	$3,240,347
GEODE CAPITAL MANAGEMENT, LLC	0.66%	2,397,923	+0.85%	0%	$3,238,240
GSA CAPITAL PARTNERS LLP	0.33%	1,202,906	-58%	0.14%	$1,624,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.32%	1,144,632	+30%	0%	$1,545,253
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.26%	962,060	+27%	0%	$1,298,781
STATE STREET CORP	0.24%	880,121	+7.5%	0%	$1,188,163
Schonfeld Strategic Advisors LLC	0.23%	825,633	-82%	0.01%	$1,114,603
Hennion & Walsh Asset Management, Inc.	0.21%	779,212	-1.8%	0.04%	$1,051,936
ROYAL BANK OF CANADA	0.2%	722,183	-6.7%	0%	$975,000
JACOBS LEVY EQUITY MANAGEMENT, INC	0.19%	692,727		0%	$935,181
TWO SIGMA INVESTMENTS, LP	0.15%	559,008	+38%	0%	$754,661
Invesco Ltd.	0.14%	521,403	+24%	0%	$703,894
JANE STREET GROUP, LLC	0.13%	456,530	-43%	0%	$616,315
Compagnie Lombard Odier SCmA	0.11%	410,000	+24%	0.01%	$553,500
NORTHERN TRUST CORP	0.1%	369,794	-11%	0%	$499,222
UBS Group AG	0.1%	352,922	-12%	0%	$476,445
Monaco Asset Management SAM	0.1%	350,000	-34%	0.18%	$472,500

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q4	25,569	$29,270	-$21,149			115%	3
2025 Q3	255,139,258	$344,428,817	-$1,111,877	$366,840	$3,378,705	135%	121
2025 Q2	256,351,483	$243,001,931	-$6,845,403	$130,694	$405,298	94.57%	122
2025 Q1	265,798,368	$122,476,684	-$18,141,549	$35,608	$145,514	46.08%	123
2024 Q4	297,661,697	$220,126,276	-$8,084,084	$131,426	$38,071	73.85%	123
2024 Q3	288,616,985	$453,067,680	-$48,604,219	$209,424	$720,202	157%	134
2024 Q2	278,343,151	$467,625,553	+$175,856,986	$480,648	$1,036,728	168%	122
2024 Q1	171,815,966	$412,350,994	-$23,364,054	$987,840	$5,060,160	240%	115
2023 Q4	37,359	$57,159				153%	1
2023 Q3	188,793,708	$205,786,090	-$5,677,219	$236,530	$78,371	109%	109
2023 Q2	191,289,333	$438,068,397	+$104,509,183	$743,083	$74,196	229%	120
2023 Q1	145,600,839	$353,808,775	-$2,996,169	$229,149	$319,852	243%	102
2022 Q4	146,851,787	$280,483,904	-$3,976,857	$58,064	$202,922	191%	98
2022 Q3	148,872,381	$357,281,877	+$72,587,732	$54,000	$132,000	239.98%	97
2022 Q2	118,778,588	$220,939,693	-$2,396,485	$77,000	$163,000	186%	81
2022 Q1	120,193,671	$251,305,091	-$5,492,284	$58,000	$102,000	209%	101
2021 Q4	121,371,382	$478,153,149	-$1,634,679	$486,000	$352,000	394%	104
2021 Q3	121,106,350	$582,529,732	+$17,666,644	$283,000	$566,000	480.99%	95
2021 Q2	117,674,290	$540,050,653	+$1,971,705	$974,000	$1,249,000	458.99%	103
2021 Q1	121,215,452	$711,536,085	+$170,291	$1,115,000	$1,897,000	586.98%	104
2020 Q4	50,793,575	$173,708,864	+$28,597,246	$1,100,000	$1,701,000	341.97%	98
2020 Q3	100,171,892	$144,237,719	-$4,783,608	$146,000	$239,000	143.96%	80
2020 Q2	106,956,024	$213,371,923	+$4,597,905	$114,000	$175,000	199.48%	95
2020 Q1	104,712,050	$204,188,139	-$17,126,476	$164,000	$236,000	195%	101
2019 Q4	106,725,685	$442,901,336	+$21,004,286	$752,000	$1,276,000	414.98%	106
2019 Q3	102,373,194	$308,172,526	-$29,698,348	$1,118,000	$895,000	301%	93
2019 Q2	105,032,153	$660,602,362	+$7,244,092	$2,724,000	$842,000	629%	103
2019 Q1	104,159,125	$579,079,451	-$5,053,246	$4,902,000	$1,178,000	556%	109
2018 Q4	104,810,011	$695,888,313	-$17,939,057	$1,178,000	$556,000	664%	113
2018 Q3	103,033,219	$1,099,466,789	-$14,530,643	$2,847,000	$2,917,000	1,067%	109
2018 Q2	104,283,734	$1,251,451,056	+$2,198,024	$1,924,000	$4,604,000	1,200%	109
2018 Q1	109,688,292	$939,105,485	-$14,255,378	$1,332,000	$450,000	856.93%	118
2017 Q4	111,171,985	$1,098,395,141	-$43,679,643	$1,333,000	$1,108,000	987.99%	122
2017 Q3	110,479,123	$1,357,785,811	-$5,734,534	$12,214,000	$1,739,000	1,229%	127
2017 Q2	110,443,040	$1,816,614,643	+$18,278,516	$1,342,000	$15,950,000	1,645%	124
2017 Q1	109,256,926	$1,566,725,760	+$112,509,097	$3,793,000	$2,009,000	1,433.95%	127
2016 Q4	105,664,118	$1,461,478,819	-$2,371,859	$1,562,000	$5,418,000	1,382.98%	135
2016 Q3	106,019,354	$1,915,064,558	-$1,509,787	$3,714,000	$6,858,975	1,806.97%	135
2016 Q2	110,551,221	$1,586,392,524	+$1,155,777	$7,551,000	$5,336,000	1,434.98%	131
2016 Q1	110,609,150	$1,321,614,000	+$12,384,134	$3,259,000	$3,532,000	1,195%	123
2015 Q4	109,648,754	$1,459,670,001	+$54,954,952	$11,088,000	$6,907,000	1,330.99%	115
2015 Q3	105,843,715	$1,136,734,006	+$97,681,198	$895,000	$10,896,000	1,074%	98
2015 Q2	96,418,831	$776,171,263	+$741,386,807			805%	85